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Purpose: There was a global increase in the prevalence of oseltamivir-resistant influenza viruses 
during the 2007–2008 influenza season. This study was conducted to investigate the occurrence and 
characteristics of oseltamivir-resistant influenza viruses during the 2007–2008 and 2008–2009 influenza 
seasons among patients who were treated with oseltamivir (group A) and those that did not receive 
oseltamivir (group B). 
Methods: A prospective study was conducted on 321 pediatric patients who were hospitalized because of 
influenza during the 2007–2008 and 2008–2009 influenza seasons. Drug resistance tests were con-
ducted on influenza viruses isolated from 91 patients.
Results: There was no significant difference between the clinical characteristics of groups A and B 
during both seasons. Influenza A/H1N1, isolated from both groups A and B during the 2007–2008 
and 2008–2009 periods, was not resistant to zanamivir. However, phenotypic analysis of the virus revealed 
a high oseltamivir IC50 range and that H275Y substitution of the neuraminidase (NA) gene and 
partial variation of the hemagglutinin (HA) gene did not affect its antigenicity to the HA vaccine even 
though group A had a shorter hospitalization duration and fewer lower respiratory tract complications 
than group B. In addition, there was no significant difference in the clinical manifestations between 
oseltamivir-sus  ceptible and oseltamivir-resistant strains of influenza A/H1N1.
Conclusion: Establishment of guidelines to efficiently treat influenza with oseltamivir, a commonly 
used drug for treating influenza in Korean pediatric patients, and a treatment strategy with a new the-
rapeutic agent is required. 
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Introduction  
Influenza has been occurring every year, on a large scale. Thus, it may cause huge 
socioeconomic loss. In addition, due to the possibility of the appearance of novel viruses 
every year caused by frequent antigenic variation of virus, it may cause high mortality
1). 
Accordingly, antigenic variation of the influenza virus has been continuously monitored via a 
worldwide surveillance program to develop vaccines and to investigate pandemic status
2). http://dx.doi.org/10.3345/kjp.2013.56.4.165
SG Kim, et al. • A study on oseltamivir-resistant influenza virus  
166
Preventive vaccination is important for influenza prevention. In 
addition to the preventive vaccination, antiviral agents also play 
an important role in the treatment of influenza
3). Aman  tadine and 
rimantadine, M2 inhi bitors, are ineffective in the influenza B virus 
infection, without the M2 protein, due to a rapid increase of drug 
resistance and side effects in the central nervous system; their use is 
limited in pediatric patients
4,5).
Oseltamivir (Tamiflu), a neuraminidase (NA) inhibitor, has been 
approved for the prevention and treatment of influenza A and B 
in pediatric patients, aged one year or higher and in adult patients, 
and has been used worldwide since 2001
3). However, few studies 
on oseltamivir have been conducted on Korean pediatric pati  ents. 
Accordingly, the authors randomly divided the influ  enza patients 
during 2007–2008 and 2008–2009 influenza seasons. In to the 
oseltamivir treatment group and oseltamivir nontreat  ment group, 
and investigated the efficacy, short-term and long-term adverse 
events, and safety of oseltamivir treatment. As a result, the authors 
showed that oseltamivir treatment had clinical efficacy and 
safety in pediatric patients by shortening hospitalization duration 
and reducing lower airway compli  cations without other serious 
adverse events including neuro  psychiatric problems for both 
2007–2008 and 2008–2009 influ  enza seasons
6).
However, since its commercialization, increase in oseltamivir 
resistance by virus has been reported since 2004
7,8), and has been 
reported worldwide since 2007–2008
9). In addition, in Korea, 
influenza sample surveillance during 2008–2009 influenza season 
showed that oseltamivir resistance was shown in 99.7% of A/H1N1 
virus isolates
10). The occurrence of oseltamivir-re  sistant virus may 
decrease chemoprophylaxis and efficacy for the influenza virus. In 
particular, drug-resistant virus occurs more frequently in pediatric 
patients than in adult patients, due to limited immunity and long-
term virus release in children
8,11), and the occurrence of drug-
resistant virus in children not only affects the individual pediatric 
patient, but also becomes a very important issue in terms of public 
health. Accordingly, this study was conducted to investigate the 
occurrence and resistance mechanism of oseltamivir-resistant virus 
between the oseltamivir treatment and non-treatment groups, 
during 2007–2008 and 2008–2009 influenza seasons. 
Materials and methods 
1. Subjects, oral administration of oseltamivir, and disease history 
review 
The authors previously reported a clinical study on the effi  cacy, 
short-term and long-term side effects, and safety of oseltamivir 
in pediatric patients infected with influenza virus
6). The sum  mary 
of the clinical study was as follows. Of the pediatric pa  tients with 
respiratory symptoms who visited the outpatient and emergency 
room in the department of pediatrics at Busan St. Mary's Medical 
Center, during the two influenza seasons (9 months), January 2008   
to June 2008 (first study period) and November 2008 to January 
2009 (second study period) those with influenza-like symptoms 
were selected. As for the influenza-like symptom, it was defined 
as a status of 37.8℃ or higher fever as a main symptom with one or 
more systemic symptoms (fatigue, headache, muscle pain, chill) and 
respira  tory symptoms (cough, pharyngitis, nasal discharge, nasal 
congestion) by referring to the definition of the National Insti  tute 
of Health
12). But, children of less than 2 years old age were enrolled 
into the study if they had an temperature ≥37.8℃ and at least one 
respiratory symptoms (cough or coryza). 
Nasal discharge was collected from the patients, and then quick 
influenza test (SD Bioline Influenza Antigen Test kit; Quidel Co., 
San Diego, CA, USA), a rapid antigen test (RAT), was conducted to 
diagnose the influenza. The same tests were performed during two 
periods. The RAT positive in all patients, a total of 537 pediatric 
patients (first study period 318, second study period 219) who were 
diagnosed as positive to influenza and hospitalized. All parents of 
influenza patients provided written informed consent.
The study was prospectively conducted after receiving the 
informed consent forms from the participating patients. Among 
parents of 537 patients, 321 parents’ consent and their child 
participated in the study and assigned to the oseltamivir treat  ment 
group (A group) and oseltamivir nontreatment group (B group) 
based on the assigning to the each attending doctor. Study exclusion 
criteria included: children with respiratory syncytial virus infection 
(RAT); cyanotic heart disease; children with immunosuppressed 
(drugs, transplant recipient, malig  nancy or human immunodefi-
ciency virus infection); history of acetaminophen allergy docu-
mented. Throat swab or nasopharyn  geal swab was collected from 
the RAT positive in all patients, upon admission and 48 to 72 hours 
after admis  sion, tests were performed two times, and transferred 
to Busan Institute of Health and Environment for virus culture. 
Immediately after virus culture, the A group received oseltamivir, 
antiviral agent, and twice a day for 5 days. Meanwhile, the B group 
received symptom controlling agent when they had influenza-like 
symptoms. The treatment dose was 30 mg for body weight of 15 kg 
or less, 45 mg for body weight of 16 to 23 kg, and 60 mg for 24 to 
40 kg, and 75 mg for body weight of 40 kg or more in patients aged 
1 to 12 years. The drug was administered twice a day for 5 days. 
Meanwhile, the drug was administered at a dose of 75 mg, twice a 
day for 5 days, in the pediatric patients aged 13 years or higher. 
Of the 321 pediatric patients, who were hospitalized due to 
influenza, viruses were identified by culture in 190 patients (first 
study period 150 patients, second study period 40 patients). Drug 
resistance test was conducted on 91 patients (first study period 51 
patients, second study period 40 patients) among the 190 culture 
proven patients. However, in the first study period, drug resistance 
test was conducted by 20% random sampling in the Centers for 167 http://dx.doi.org/10.3345/kjp.2013.56.4.165
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Disease Control because of limitation of la  boratory environment. 
The pediatric patient’s sex, age, preven  tive vaccination taking and 
clinical data including fever and admission duration were reviewed, 
using their medical records. The study has been approved by the 
Institutional Review Board of Busan St. Mary's Medical Center 
before the study initiation. 
2. Methods of virus detection 
1) Culturing and RNA analysis of influenza virus 
Throat and nasopharyngeal swabs were collected using a 
sterilized cotton stick from the pediatric patients who were 
hospitalized after being diagnosed as positive to influenza as a 
result of a RAT, and stored in a refrigerator. They were put into a 
viral transport medium (VTM; Difco Laboratories, Detroit, Ml, USA), 
and then transferred to Busan Institute of Health and Environment, 
while maintaining a 4℃, followed by virus culture. Mardin-Darby 
Canine Kidney (MDCK) cell line, provided by the department of 
influenza virus of the Center for Disease Control and Prevention 
(CDC), was cultured on minimum essential medium (MEM; Gibco, 
Carlsbad, CA, USA), containing penicillin (0.05 U/mL), streptomycin 
(0.05 μg/mL), and 10% fetal bovin serum (FBS; Gibco USA) in a 
5% CO2 incubator at 37℃. For specimen pretreatment, penicillin 
(5 U/mL), streptomycin (5 μg/mL), and nystatin (1,000 units/mL) 
were added to the VTM, and were placed at 4℃ for one hour, while 
shaking at an interval of 15 minutes, followed by centrifugation 
(2,000 rpm, 20 minutes, 4℃). The supernatant obtained from the 
centrifugation was used as a specimen for virus inoculation. For 
virus isolation, 200 μL pretreated speci  men and MDCK inoculation 
culture solution 500 μL were multiply inoculated on 3 wells of the 
MDCK cell line that was monolayer-cultured in a 24 well culture 
vessel, followed by culturing in a CO2 incubator at 5% CO2, 
35℃ for 7 to 10 days. The cells were observed on a daily basis, 
under an inverted mi  croscope. If 80% or more cytopathic effect 
(CPE) was observed, the cells were collected and then centrifuged 
(10,000 rpm, 10 minutes, 4℃) to separate the supernatant and cell 
sediments, and were stored at -70℃ before use. If necessary, they 
were sequentially cultured 2–3 times to increase the titer, and 
the culture solution and infected cells were obtained for virus 
iso  lation and identification. Virus identification was performed 
via hemagglutination inhibition test and reverse transcription-
polymerase chain reaction (RT-PCR). For RT-PCR, RNA was 
isolated from the virus culture solution with CPE, using a ZR 
viral RNA kit (Zymo Research Co., Irvine, CA, USA), followed by RT-
PCR to analyze the virus subtype (A/H1N1, A/H3N2, and B).
2) Antiviral agent resistance test 
Influenza antiviral agent drug resistance test was conducted via 
genotypic and phenotypic analyses (Fig. 1). For the pheno  typic 
analysis, NA inhibitors (oseltamivir, zanamivir) were used, according 
to fluorometric NA inhibition assay (World Health Organization 
[WHO]-025), which is the standard assay provided by the WHO 
Collaborating Centre for Reference and Research on Influenza. After 
NA inhibitor was prepared to have a concentration of 0–30,000 
nM, 50 μL of the NA inhibitor was put into a 96 well black plate. 
Influenza virus of 50 μL was added to each well, and 1× AB 50 μL 
was added to the last well, as the control, followed by a reaction at 
RT for 45 minutes. 50 μL methylumbelliferone N-acetylneuraminic 
acid was added to each well, and then reacted at 37℃for 1 hour, the 
reaction was halted by adding 100 μL stop solution, and absorbance 
was measured at 360 nm and 448 nm. Amount of NAI required to 
inhibit 50% of viral NA activity, 50% inhibitory concentration (IC50 
[nM]) values for each virus was obtained, using a Prism 4.0 program. 
According to the criteria presented in the Australian Influenza 
Reference Laboratory the virus was adjudged to be a sensitive strain 
in the case of IC50 value of 0.001-25 nM, and resistant strain in the 
case of IC50 value of 43-8,020 nM. 
For the genotypic analysis, mutations of amino acid regions 
related to drug resistance (E119V, R152K, H274Y, R292K, and 
N294S) were examined, via sequence analysis of NA gene. RT-PCR 
was conducted using primers specific for NA gene of influenza 
viruses isolated during the second study period  and RT-PCR 
premix (AccuPower RT/PCR PreMix, Bioneer, Daejeon, Korea) 
according to Jung’s method (2008)
13). That is, strand RNA and 
reverse primer mixture were reacted at 70℃ for 5 minutes, and 
then immediately transferred on the ice, followed by a reaction 
for 5 minutes. Then, forward primer was added and reacted 
at 42℃ for 1 hour to prepare cDNA. Subsequently, PCR was 
conducted under the conditions of 94℃ for 1 minute, 61℃ for 
1 minute, 72℃ for 1 minute, and 35 cycles. The PCR product 
underwent electrophoresis at 1.5% agarose gel (0.5×tris-acetate-
ethylenediaminetetraacetic acid) to identify NA gene-specific PCR 
product. The PCR product was purified using PCR purification 
(Bioneer) and gel extraction kit (Qiagen, Valencia, CA, USA), 
Fig. 1. Flowchart of detection of and drug-resistant analysis for influenza 
viruses. T-PCR, reverse transcriptionpolymerase chain reaction.http://dx.doi.org/10.3345/kjp.2013.56.4.165
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followed by nucleotide analysis using ChromasPRO, EditSeq and 
MegAlign (DNASTAR, Madison, WI, USA). PAUP ver. 4.0 was used 
for genetic distance and phylogenetic tree. A comparative analysis 
was conducted using the finally identified nucleotide sequences 
among the WHO recommended vaccines, foreign isolates, and 
domestic isolates.   
3. Statistical analysis 
Statistical analysis was conducted using the SPSS ver. 12.0 
(SPSS Inc., Chicago, IL, USA). Continuous values were expressed as 
the mean and standard deviation. Chi-square test was conducted 
for analyzing qualitative factors, and independent t-test, Mann-
Whitney, and Kolmogorov-Smirnov tests were conducted for the 
analysis of quantitative factors, depending on the presence of normal 
distribution in the data. If P value was <0.05, it was considered 
statistically significant.
Results 
1. Clinical characteristics and clinical final diagnosis of the 
osel  tamivir treatment group and nontreatment group during 
the study period
There was no difference in age between the oseltamivir treat  ment 
(group A) and nontreatment (group B) for both proven influenza 
patients group during the first study period and second study period, 
although there was significant difference for resistance analysis 
group during the first study period. No significant differences in the 
gender ratio, previous history of influenza infection and previous 
history of preventive vac  cination against influenza were found 
between the two groups during the first and second periods (Table 
1). Regarding fever duration before admission and prefever <48 
hours at admission (as duration of time between fever onset and 
admission point is less than 48 hours), there was no significant 
difference in resistance analysis group during the first study period 
and second study period, although there was significant difference 
among proven influenza patients group during the first study 
period. No significant difference in fever duration after admis  sion 
was found between the two groups for both periods. Group A had 
significant shorter in admission duration than group B for both 
proven influenza patients group in the first study and second study 
periods, although there was no difference for resistance analysis 
group during the first study period (Table 1). Group A had lesser 
frequency in pneumonia than group B for both proven influenza 
patients group in the first study and second study periods, although 
there was no difference for resistance analysis group during the 
first study period (Table 2). There was no significant difference of 
respiratory complications other than pneumonia, febrile convulsion 
and acute otitis media between the two groups during the first and 
second periods. 
2. Results of influenza virus culturing 
Of the 321 patients who were hospitalized in the department 
of pediatrics during the two seasons, virus was isolated from 190 
patients (59.2%). Virus was isolated in 82 patients (59.0%) of the 
group A and 68 patients (63.6%) in the group B during the first 
study period, whereas, it was isolated in 27 patients (57.4%) of the 
group A and in 13 patients (46.4%) of the group B during the second 
study period. The results of influenza virus culturing was as follows 
(Fig. 2).
There was no difference in influenza A/H1N1, A/H3N2, and B 
between the groups A and B for both resistance analysis group and 
culture proven patients group during the first study period and 
Table 1. Clinical characteristics of the oseltamivir treatment group and nontreatment group during the study period
Characteristic
First study period Second study period
Resistance analysis group (n=51) Proven influenza patients group (n=150) Resistance analysis group (n=40)
Group A (n=29) Group B (n=22) P value* Group A (=82) Group B (n=68) P value* Group A (n=27) Group B (n=13) P value*
Age (yr) 3.1 (0.1–9.1) 5.1 (0.1–14.1) 0.02 4.0 (0.1–13.0) 4.1 (0.1–14.0) 0.59 3.1 (0.1–12.1) 3.1 (0.1–15.1) 0.78
Male gender 12 (41.4) 9 (40.9) 0.97 41 (50.0) 27 (39.7) 0.21 17 (63.0) 5 (38.5) 0.19
Previous history of 
 influenza infection
0 (0) 0 (0) - 0 (0) 0 (0) - 0 (0) 1 (7.7) 0.33
Preventive vaccination 
 against influenza
11 (37.9) 10 (45.5) 0.59 31 (37.8) 31 (45.6) 0.34 14 (51.9) 7 (53.8) 0.91
Prefever (day) 2.5±1.2 (1–5) 2.1±1.5 (1–7) 0.30 2.4±1.3 (1–6) 2.0±1.3 (1–7) 0.02 2.0±1.0 (1–4) 2.1±1.1 (1–5) 0.91
Prefever <48
† (hr) 8 (27.6) 10 (45.5) 0.19 23 (28.0) 31 (45.6) 0.03 9 (33.3) 4 (30.8) 1.00
Afterfever (day) 1.1±1.2 (1–5) 1.0±0.8 (1–3) 0.87 1.0±1.0 (1–5) 0.9±1.0 (1–4) 0.62 0.6±0.9 (1–4) 0.7±1.0 (1–4) 0.69
Admission (day) 5.0 (3.0–9.0) 5.0 (3.0–8.0) 0.78 4.0 (2.0–9.0) 5.0 (2.0–15.0)   0.049 4.0 (3.0–8.0) 5.0 (3.0–8.0) 0.05
Values are presented as median (range), number (%), or mean±standard deviation (range).
Group A, treatment group; group B, oseltamivir nontreatment group; 'Prefever, duration of time between fever onsets an admission point; Afterfever, time duration 
since admission.
*P<0.05. 
†Prefever<48 at admission means duration of time between fever onset and admission point is less than 48 hours. 169 http://dx.doi.org/10.3345/kjp.2013.56.4.165
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second study period (Table 3). That is, influenza B and A/H1N1 were 
dominantly isolated in the influenza infected patients during the 
first study period and second study period, respectively. 
3. Results of phenotypic analysis of antiviral resistance 
During the first study period, oseltamivir IC50 value of in  fluenza 
A/H1N1 was shown to be 0.25±0.34 in group A and 0.28±0.14 nM 
in group B. Zanamivir IC50 value was shown to be 1.16±1.25 in 
group A and 2.22±1.37 nM in group B. This result showed that both 
groups had sensitivity to oseltamivir and zanamivir. In addition, 
both groups were shown to have sensitivity to both oseltamivir 
and zanamavir for influenza A/H3N2 and B. However, during the 
second study period, oseltamivir IC50 of influenza A/H1N1 was 
shown to be 539.37±143.08 nM in group A and 496.33±89.62 nM 
in group B, which showed that both groups had high-level drug 
resistance, and that no significant difference was found between 
the two groups although zanamivir IC50 of the both groups was 
shown to be sensitive to zanamivir as shown in the first study 
period. Influenza A/H3N2 was isolated from group A during the 
second study period, respectively. Oseltamivir and zanamivir IC50 of 
influenza A/H3N2 was shown to have ranged within sensitivity like 
first study period (Table 4).
In addition, the change of phenotypic resistance of influenza 
A/H1N1, A/H3N2, and B between admission and 48 to 72 hours 
after admission showed that no difference in oseltamivir IC50 and 
zanamivir IC50 was found between two time points for both groups 
during the first study period and second study period (Table 5).
4. Result of analysis of antiviral resistance gene
NA gene analysis was conducted on influenza viruses isolated from 
Table 2. Final clinical diagnosis of the oseltamivir treatment group and nontreatment group during the study period
First study period Second study period
Resistance analysis group (n=51) Proven influenza patients group (n=150) Resistance analysis group (n=40)
Group A (n=29) Group B (n=22) P value* Group A (=82) Group B (n=68) P value* Group A (n=27) Group B (n=13) P value*
Influenza only 8 (27.6) 10 (45.5) 0.19 31 (37.8) 22 (32.4) 0.49 13 (48.1) 2 (15.4) 0.08
With pneumonia 4 (13.8) 7 (31.8) 0.17 19 (23.2) 27 (39.7) 0.03 6 (22.2) 7 (53.8) 0.045
With bronchitis 8 (27.6) 1 (4.5) 0.06 18 (22.2) 10 (14.7) 0.26 1 (3.7) 2 (15.4) 0.24
With croup 4 (13.8) 1 (4.5) 0.38 6 (7.3) 2 (2.9) 0.29 0 (0) 0 (0) -
With asthma aggrevation 2 (6.9) 2 (9.1) 1.00 2 (2.4) 5 (7.4) 0.25 3 (11.1) 2 (15.4) 1.00
With bronchiolitis 0 (0) 0 (0) - 1 (1.2) 0 (0) 1.00 4 (14.8) 0 (0) 0.28
With febrile-convulsion 1 (3.4) 0 (0) 1.00 3 (3.7) 2 (2.9) 1.00 2 (7.4) 1 (7.7) 1.00
With acute otitis media 2 (6.9) 3 (13.6) 0.64 4 (4.9) 7 (10.3) 0.23 1 (3.7) 1 (7.7) 1.00
Values are presented as number (%).
Group A, treatment group; group B, oseltamivir nontreatment group.
*P<0.05.
Table 3. Subtypes of influenza virus isolated from specimens during the study period
Subtype
First study period Second study period 
Resistance analysis group (n=51) Proven influenza patients group (n=150) Resistance analysis group (n=40)
Group A (n=29) Group B (n=22) P value* Group A (=82) Group B (n=68) P value* Group A (n=27) Group B (n=13) P value*
A/H1N1 11 (37.9) 5 (22.7) 0.36 13 (15.9) 7 (10.3) 0.32 26 (96.3) 13 (100) 0.48
A/H3N2 4 (13.8) 2 (9.1) 0.69 11 (13.4) 9 (13.2) 0.97 1 (3.7) 0 (0) 1.00
B 14 (48.3) 15 (68.2) 0.16 58 (70.7) 52 (76.5) 0.43 0 (0) 0 (0) -
Values are presented as number (%).
Group A, treatment group; group B, oseltamivir nontreatment group.
*P<0.05.
Fig. 2. Influenza rapid antigen test, virus isolation, and phenotypic/genetic 
analysis in the treatment group and oseltamivir non-treatment group during 
the study period.http://dx.doi.org/10.3345/kjp.2013.56.4.165
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51 patients (group A, 29 patients; group B, 22 patients) during the 
first study period in order to examine the drug resis  tance-related 
mutation of NA inhibitor (E119V, R152K, H274Y, R292K, N294S). 
The result showed that no drug resistance-related mutation of NA 
inhibitor such as oseltamivir was found. 
Meanwhile, NA gene analysis was conducted on influenza virus 
A/H1N1 and A/H3/N2 isolated from 40 patients (group A, 27 
patients; group B, 13 patients) during the second study period. The 
result showed that H275Y (N1 numbering) mutation was observed 
in all of  A/H1N1 virus strains isolated from 39 patients during the 
second study period, showing NI resis  tance, and that D354G of 
NA gene was observed in most isolates. However, no amino acid 
mutation related to NI resistance was found in the A/H3N2. The NA 
gene of the domestic isolates showed 97.6% homology with that 
of A/Brisbane/59/2007, a vaccine stain of 2008–2009 influenza 
season. Thus, the domestic isolates belonged to clade 2B group 
rather than A/Solomon Islands/3/2006 (clade 2A), a vaccine strain 
of 2007–2008 influ  enza season (Fig. 3).
The nucleotide sequence of hemagglutinin (HA) gene of 37 
strains of influenza virus A/H1N1 isolated during the second study 
period was analyzed to investigate their homology with vaccine 
strains. The result showed that they had 97.1% homology with A/
Brisbane/59/2007, a vaccine strain of 2008–2009 influ  enza season, 
which showed that they belonged to clade 2B group (Fig. 3). Amino 
Table 4. Change in the phenotypic resistance of influenza A/H1N1, A/H3N2, and B between admission and 48 to 72 hours after admission: NI assay 
(phenotype analysis) with oseltamivir and zanamivir during the study period
Subtype Drug
Mean IC50 (nM)
†
First study period (n=51) Second study period (n=40)
Group A
(n=29)
Group B
(n=22)
Existence of oseltamivir 
resistance (%) P value* Group A 
(n=27)
Group B
(n=13)
Existence of oseltamivir 
resistance (%) P value*
A/H1N1 Oseltamivir 0.25±0.34 0.28±0.14 0 0.83 539.37±143.08 496.33±89.62 100 0.34
Zanamivir 1.16±1.25 2.22±1.37 0.18 0.42±0.11 0.44±0.14 - 0.69
A/H3N2 Oseltamivir 0.06±0.10 0.30±0.04 0 0.73 0.16 - 0 -
Zanamivir 0.27±0.53 0.00±0.00 0.54 0.59 - - -
B Oseltamivir 0.22±0.06 0.24±0.83 0 0.47 - - - -
Zanamivir 2.05±0.89 2.39±1.11 0.38 - - - -
Values are presented as mean±standard deviation.
IC50, 50% inhibitory concentration; group A, treatment group; group B, oseltamivir nontreatment group.
*P<0.05. 
†Oseltamivir, sensitive strain in the case of IC50 value of 0.001–25 nM, and resistant strain in the case of IC50 value of 43–8,020 nM; zanamivir, sensitive 
strain in the case of IC50 value of 0.001–15 nM, and resistant strain in the case of IC50 value of 43–8,020 nM.
Table 5. Sensitivity of influenza A/H1N1, A/H3N2, and B virus isolates to oseltamivir and zanamivir in the NI assay (phenotype analysis): both at admission and 
at 48 to 72 hours after admission during the study period
Subtype Point Drug
Mean IC50 (nM)
†
First study period (n=51) Second study period (n=40)
Group A (n=29) Group B (n=22) P value* Group A (n=27) Group B (n=13) P value*
A/H1N1 Upon admission Oseltamivir 0.21±0.29 0.30±0.19 0.66 459.81±68.31 499.07±90.44 0.20
Zanamivir 1.30±1.41 1.80±1.49 0.62   0.48±0.12   0.58±0.11 0.15
After admission (48–72 hr) Oseltamivir 0.05±0.07 0.21±0.00 0.31   0.31±0.07   0.28±0.07 0.24
Zanamivir 1.18±1.58 1.91±0.00 0.77   0.33±0.08   0.28±0.05 0.27
A/H3N2 Upon admission Oseltamivir 0.01 0.00 - 0.16 - -
Zanamivir 0.00 0.00 - 0.59 - -
After admission (48–72 hr) Oseltamivir 0.01 - - - - -
Zanamivir 0.00 - - - - -
B Upon admission Oseltamivir 0.22±0.07 0.27±0.06 0.14 - - -
Zanamivir 2.07±0.76 0.26±1.36 0.35 - - -
After admission (48–72 hr) Oseltamivir 0.25 2.59±1.36 0.98 - - -
Zanamivir 2.09 2.55±1.14 0.76 - - -
Values are presented as mean±standard deviation.
IC50, 50% inhibitory concentration; group A, treatment group; group B, oseltamivir nontreatment group.
*P value<0.05. 
†Oseltamivir, sensitive strain in the case of IC50 value of 0.001–25 nM, and resistant strain in the case of IC50 value of 43–8,020 nM; zanamivir, 
sensitive strain in the case of IC50 value of 0.001–15 nM, and resistant strain in the case of IC50 value of 43–8,020 nM.171 http://dx.doi.org/10.3345/kjp.2013.56.4.165
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acid mutations (S158N, G202A, and A206T) were shown in all the 
domestic isolates, but they were unlikely to affect antigenicity to 
vaccine strain. The isolates had 97.2% to 100.0% homology among 
them.
5. Clinical characteristics and clinical final diagnosis of the 
oseltamivir-susceptible group and oseltamivir-resistant group 
for in  fluenza A/H1N1 during the study period
There was no difference in age, gender ratio, previous history of 
influenza infection, and previous history of preventive vaccina  tion 
against influenza between the oseltamivir-susceptible group and 
oseltamivir-resistant group in overall (Table 6). In addition, there was 
no significant difference in febrile con  vulsion, acute otitis media, 
and respiratory complications be  tween the oseltamivir-susceptible 
group and oseltamivir-resistant group, except bronchitis (Table 7).
Discussion 
In this study, influenza A/H1N1 isolated from both treatment 
group and oseltamivir nontreatment group during the first study 
period (2007–2008 season) and second study period (2008–2009 
season) had no zanamivir resistance. However, phenotypic analysis 
showed that oseltamivir IC50 ranged within high-level drug 
resistance, H275Y of NA gene and partial variation of HA gene 
does not affect antigenicity to HA vaccine, even though oseltamivir 
treatment group had shorter admisson duration and fewer lower 
respiratory tract complica  tions compared to the oseltamivir 
nontreatment group. In addition, there was no significant difference 
of clinical mani  festations between oseltamivir susceptible and 
resistant periods. 
As for the clinical characteristics of treatment group and 
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oseltamivir non-treatment group during the first study period 
or second study period, no significant difference in age, gender, 
presence of preventive vaccination, and previous history of 
influenza infection was found between the two groups. The result of 
influenza virus isolation showed that influenza virus B, A/H1N1, A/
H3N2 in that order were isolated in treat  ment group and oseltamivir 
nontreatment group during 2007–2008 influenza season, and that 
influenza A/H1N1 was mainly isolated in the both groups during 
2008–2009 in  fluenza season. This result was consistent with the 
subtype distribution of 2007–2008 and 2008–2009 influenza 
sentinel surveillance reported by the center for disease control
10).
New influenza occurs each year via antigenic shift and anti  genic 
drift due to genetic changes of HA and NA genes, surface antigens. 
Antigenic shift mainly occurs by influenza A, and is classified 
into H1–H16 according to HA mutation, and into N1–N9 types 
according to NA mutation
14). HA has been known to be a main 
causative factor of antigenic mutation and involved in the binding 
of virus to cells, and NA has been known to be a surface antigen 
of influenza virus and play an important role in the secretion of 
synthesized viruses from cells, thus, they have drawn attention as 
targets of antiviral agents
3). Oseltamivir, one of NA inhibitors, is an 
oral agent that is used worldwide for the prevention and treatment 
of influenza. How  ever, since a rapid increase of oseltamivir-resistant 
influenza virus A/H1N1 was reported in Norway in January 
2008, oseltamivir-resistant strains have been spreading worldwide 
including Europe, Oceania, Southeast Asia, and Africa
9,15,16). In 
this study, no oseltamivir resistance was shown in any influenza 
subtype during the 2007–2008 season in but 100% oseltamivir 
Table 6. Clinical characteristics of the oseltamivir-susceptible group and oseltamivir-resistant group for influenza A/H1N1 during the study period
A/H1N1
Resistance analysis group (n=55) Proven influenza patients group (n=59)
Group A (n=37) Group B (n=18) Group A (n=39) Group B (n=20)
Susceptible 
group
 (n=11)
Oseltamivir-
resistant
group (n=26)
P value*
Susceptible 
group
(n=5)
Oseltamivir-
resistant
group  (n=13)
P value*
Susceptible 
group
(n=13)
Oseltamivir-
resistant
group (n=26)
P value*
Susceptible 
group
(n=7)
Oseltamivir-
resistant
group (n=13)
P value*
Age (yr) 3.41±2.57 4.00±3.34 0.62 4.86±2.39 4.38±4.65 0.82 3.59±2.46 3.97±3.34 0.72 5.35±2.14 4.38±4.65 0.61
Male gender 8 (72.7) 17 (65.4) 1.00 2 (40.0) 5 (38.5) 1.00 8 (57.1) 17 (61.5) 0.81 2 (28.6) 5 (38.5) 1.00
Previous history of 
 influenza infection
0 (0) 0 (0) - 0 (0) 1 (7.7) 1.00 0 (0) 0 (0) - 0 (0) 1 (7.7) 1.00
Preventive vaccination 
 against influenza
4 (36.4) 13 (50.0) 0.50 4 (80.0) 7 (53.8) 0.60 5 (38.5) 13 (50.0) 0.50 4 (57.1) 7 (53.8) 1.00
Prefever (day) 1.91±0.83
(1–3)
2.04±1.00
(1–4)
0.71 3.00±1.22
(1–4)
2.08±1.12
(1–5)
0.19 2.00±0.82 
(1–3)
2.04±1.00 
(1–4)
0.90 2.71±1.12 
(1–4)
2.07±1.12 
(1–5)
0.24
Prefever<48
† (hr) 4 (36.4) 9 (34.6) 1.00 1 (20.0) 4 (30.8) 1.00 4 (30.8) 9 (34.6) 1.00 1 (14.3) 4 (30.8) 0.61
Afterfever (day) 0.80±0.84
(0–3)
0.61±0.89
(0–4)
0.55 1.65±1.08
(1–3)
0.71±0.96
(0–4)
0.14 0.75±0.78 0.61±0.89 0.61 1.29±1.10 
(0–3)
071±0.96 
(0–4)
0.27
Admission (day) 4.55±1.75 4.38±1.30 0.79 4.60±1.52 5.15±1.21 0.43 4.54±1.61 4.38±1.30 0.75 5.00±1.41 5.15±1.21 0.81
Values are presented as number (%) or mean±standard deviation (range).
Group A, treatment group; group B, oseltamivir nontreatment group; 'Prefever' means duration of time between fever onsets an admission point.' Afterfever' means 
time duration since admission.
*P<0.05. 
†Prefever<48 at admission means duration of time between fever onset and admission point is less than 48 hours. 
Table 7. Final clinical diagnosis of the oseltamivir-susceptible group and oseltamivir-resistant group for influenza A/H1N1 during the study period
A/H1N1
Resistance analysis group (n=55) Proven influenza patients group (n=59)
Group A (n=37) Group B (n=18) Group A (n=39) Group B (n=20)
Susceptible 
group
(n=11)
Oseltamivir-
resistant
group (n=26)
P value*
Susceptible 
group
(n=5)
Oseltamivir-
resistant
group (n=13)
P value*
Susceptible 
group
(n=13)
Oseltamivir-
resistant
group (n=26)
P value*
Susceptible 
group
(n=7)
Oseltamivir-
resistant
group (n=13)
P value*
Influenza only  4 (36.4) 13 (50.0) 0.50 2 (40.0) 2 (15.4) 0.53 5 (38.5) 13 (50.0) 0.50 3 (42.9) 2 (15.4) 0.29
With pneumonia  1 (9.1) 6 (23.1) 0.65 3 (60.0) 7 (53.8) 1.00 1 (7.7) 6 (23.1) 0.39 3 (42.9) 7 (53.8) 1.00
With bronchitis 4 (36.4) 1 (3.8) 0.02 0 (0) 2 (15.4) 1.00 5 (38.5) 1 (3.8) 0.01 0 (0) 2 (15.4) 0.52
With croup 2 (18.2) 0 (0) 0.08 0 (0) 0 (0) - 2 (15.4) 0 (0) 0.11 0 (0) 0 (0) -
With asthma aggrevation 0 (0) 3 (11.5) 0.54 0 (0) 2 (15.4) 1.00 1 (7.1) 3 (11.5) 1.00 1 (14.3) 2 (15.4) 1.00
With bronchiolitis 0 (0) 3 (11.5) 0.54 0 (0) 0 (0) - 0 (0) 3 (11.5) 0.54 0 (0) 0 (0) -
With febrile-convulsion 1 (9.1) 2 (7.7) 1.00 0 (0) 1 (7.7) 1.00 1 (7.7) 2 (7.7) 1.00 0 ()) 1 (7.7) 0.45
With acute otitis media 1 (9.1) 1 (3.8) 0.51 1 (20) 1 (7.7) 0.49 1 (7.7) 1 (3.8) 1.00 1 (14.3) 1 (7.7) 1.00
Values are presented as number (%).
Group A, treatment group; group B, oseltamivir nontreatment group.
*P value<0.05. 173 http://dx.doi.org/10.3345/kjp.2013.56.4.165
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resistance was shown in all the influenza A/H1N1 strains during 
the 2008–2009 season in accordance to domestic data
10). The results 
of genotype analysis revealed H275Y (N1 numbering) mutation, 
which was consistent with those of previous studies
9,16). In addition, 
the result of phenotype analysis showed that zanamivir IC50 ranged 
within sensitivity, but that oseltamivir IC50 ranged beyond the 
maximum concentration, showing oseltamivir resistance. This was 
also consistent with those of the previous studies
17).
Oseltamivir-resistant virus before 2007–2008 season was mainly 
reported in pediatric patients who received oselta  mivir
8), and human 
to human transmission has been rarely reported
18). However, in 
the cases of pediatric patients infected with oseltamivir-resistant 
virus isolated in US during 2007–2008 season and in Italy during 
2007–2008 and 2008–2009 seasons, they had no previous history of 
oseltamivir admini  stration
19,20). In this study, although the previous 
history of oseltamivir administration was not checked in all the 
pediatric patients, most of pediatric patients during 2008–2009 
influ  enza seasons had no previous history of oseltamivir admini-
stration. Thus, the occurrence of oseltamivir-resistant virus during 
2008–2009 seasons is unlikely to be relevant to oseltamivir 
administration. 
In Japan, the rate of oseltamivir-resistant influenza A/H1N1 was 
shown to be 2.5% during 2007–2008 season, but 100% during 
2008–2009 season
21). Matsuzaki et al.
21) reported that when the 
genetic analysis of phylogenic tree was conducted, oseltamivir-
resistant A/H1N1 that was prevalent in Japan during 2007–2008 
season was different from oseltamivir-resistant A/H1N1 that 
was prevalent in Europe and North America during 2007–2008 
season, but oseltamivir-resistant A/H1N1 that was prevalent in 
Japan during 2008–2009 season showed high ho  mology with 
oseltamivir-resistant A/H1N1 that was prevalent in Europe and 
North America during 2007–2008 influenza season. In this study, 
oseltamivir-resistant influenza A/H1N1 type during 2008–2009 
seasons had H275Y mutation of NA gene and D354G mutation, 
which was genetically close to osel  tamivir-resistant A/H1N1 that 
was prevalent in Europe and North America during 2007–2008 
season
9). In addition, the analysis of virus culture isolated upon 
admission and 48 to 72 hours after admission showed that the 
occurrence rate of oseltamivir-resistant influenza was zero both 
in the treatment group and in the oseltamivir nontreatment group 
during 2007–2008 season. The occurrence of oseltamivir-resistant 
influenza A/H1Nl during second study period was unlikely to 
have oc  curred due to oseltamivir administration during first study 
period. It is likely that oseltamivir-resistant influenza A/H1N1 that 
was prevalent in Europe and North America during 2007–2008 
influenza seasons have been imported to Japan or Korea like 
the results of other studies
21). Esposito et al.
20) studied pediatric 
patients who were infected with influenza during 2007–2008 
and 2008–2009 seasons, and reported that the H275Y mutation 
rate of influenza A/H1N1 was 1.6% during 2007–2008 influenza 
season, and 100% during 2008–2009 influenza season, and they 
also reported that no difference in the patient’s characteristics and 
hospitalization duration was found between pediatric patients 
infected with oseltamivir-resistant influenza A/H1N1 and those 
infected with wild-type seasonal A/H1N1 in compatible with this 
study . The authors’ previous study also reported that no significant 
difference in the clinical manifestations of the patients was found 
between 2007–2008 influenza season when no oseltamivir-
resistant influenza was shown and 2008–2009 influenza season 
when oseltamivir-resistant influenza A/H1N1 was 100% shown
6). 
However, Dharan et al.
19) reported that despite the similar clinical 
manifestations of patients infected with oseltamivir-resistant 
influenza A/H1N1 and with oseltamivir-susceptible influenza A/
H1N1, four patients of the 99 patients infected with oseltamivir-
resistant influenza A/H1N1 died, and that oseltamivir-resistant 
influenza A/H1N1 had serious clinical manifestations, such as 
death. They also reported that one of the four dead patients was 
a previously healthy female patient aged 4 years, and that severe 
clinical manifestation with osel  tamivir-resistant influenza infection 
could be found even in healthy children.
The authors’ previous study
6) reported that compared to the 
oseltamivir nontreatment group, shorter admission duration 
and fewer lower respiratory tract complications occurred in the 
treatment group during the 2007–2008 season with no occurrence 
of oseltamivir-resistant influenza A/H1N1, and the 2008–2009 
season with oseltamivir-resistant influenza A/H1N1 in accordance 
to this study.      
Mitamura et al.
22) reported that oseltamivir treatment was initiated 
within 48 hours of the onset of fever, 44% of the patients became 
afebrile (<37.5℃) within one day, and 86% of them reco  vered 
within two days and the average duration of fever after the initiation 
of oseltamivir treatment was 1.7 days in contrast to this study. We 
suggested that frequency of duration of time between fever onset 
and admission point is less than 48 hours was lesser in oseltamivir 
treatment group compared than osel  tamivir nontreatment 
group in this study and effectiveness of oseltamivir treatment 
against influenza virus infection in children was attenuated and 
underestimated.   
As no difference in the fever duration was found in the treat-
ment group, between the first (oseltamivir-susceptible period) 
and second study periods (oseltamivir-resistant period) after 
oseltamivir administration in both previous study
6) and this 
study, it seemed that no significant difference in the efficacy of 
oseltamivir between the first study period and second study period 
where oseltamivir-resistant virus appeared. However, Matsuzaki 
et al.
21) reported that oseltamivir efficacy could be reduced more 
in the oseltamivir-resistant strains as the fever persistency after 
oseltamivir administration was longer in the patients infected with 
oseltamivir-resistant influenza A/H1N1 than in the patients infected 
with oseltamivir-susceptible influ  enza A/H1N1. Tamura et al.
23) http://dx.doi.org/10.3345/kjp.2013.56.4.165
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reported that virus shedding time was shorter in pediatric patients 
who underwent zanami  vir treatment than in pediatric patients who 
underwent osel  tamivir treatment, in a study conducted on 144 
pediatric pati  ents during 2005–2006, 2006–2007, 2007–2008, and 
2008–2009 influenza seasons, and that no zanamivir-resistant strain 
was found in the patients who underwent zanamivir treatment, 
and they concluded that zanamivir was better than oseltamivir in 
the treatment of pediatric influenza. Currently, CDC and Ame-
rican Academy of Pediatrics define oseltamivr and zanamivir, 
which are NA inhibitors, as the therapeutic agents for influenza A 
and B, including 2009–2010 pandemic H1N1 strain in the cases 
of influenza-infected high-risk group, who might have influenza 
complications, including pediatric patients aged less than 2 years, 
child hospitalized with presumed influenza, and children with 
confirmed or suspected influenza who have severe, complicated, or 
progressive illness
24,25). Thus, a further study on efficient treatment 
strategies on pediatric influenza is required. 
In addition, unlike the 2007–2008 season, the influenza A/
H1N1 isolated during 2008–2009 season had high oseltamivir 
IC50 in the phenotypic analysis, and had H275Y (N1 numbering) 
mutation in the genotypic analysis, showing that NI-resistant 
virus was prevalent. As they were genetically close to oselta  mivir-
resistant virus, reported in Europe and North America during 
2007–2008 seasons, oseltamivir-resistant influenza A/H1N1 virus 
seems to have been rapidly made its way to Korea during the two 
influenza seasons. Although the exact me  chanism of the importing 
of oseltamivir-resistant influenza to Korea is difficult to elucidate 
in this study, it is likely that due to the mutation of NA gene and 
mutation of HA gene, immu  nogenicity to oseltamivir-resistant virus 
as well as antibody formation have decreased
26). 
Although there were some amino acid variations (158, 202, 
206) in HA gene of oseltamivir-resistant influenza A H1N1 virus 
identified during 2008–2009 study period, it was confirmed that 
there was no change of antigencity of strain due to these amino acid 
variations based on data of hemagglutination inhibition of domestic 
and foreign strains
27). Specially, because that A/Brisbane/59/2007 
was used as vaccine strain during 3 years before outbreak of H1N1 
2008/2009, we assumed that there was no considerable effect on 
antigenicity of vaccine strain based on genetic and serological 
analysis during this period. In addition, as the analysis of HA gene 
of national NI-resistant viruses showed that all of them were similar 
to vaccine of the corresponding year; efficient prevention can be 
performed via vaccination. 
Considering that the frequency of drug-resistant influenza virus 
is higher in children than in adults, and that the occurrence of these 
drug-resistant influenza viruses affects not only the individual 
health of children, but also public health, this study is meaningful in 
that it was a first study prospectively conducted on Korean children, 
despite a disadvantage of a single institution study. In addition, 
the results of this study could be useful for establishing more 
detailed monitoring on drug-resistant in  fluenza virus that occurs 
continuously, and for establishing treatment strategies for treating 
pediatric patients infected with annual prevalent influenza.
In conclusion, based on the our knowledge, this study was the 
first study to investigate Korean pediatric patients infected influ-
enza virus (two groups based on the oseltamivir treament), their 
oseltamivir resistance, NA H275Y protein variation, partial variation 
of HA in the influenza A/H1N1 virus isolated from both oseltamivir 
treatment and non-treatment groups, during the progression from 
the first study period to the second study period even though 
oseltamivir treatment group had shorter admission duration 
and fewer lower respiratory tract complica  tions compared to the 
oseltamivir nontreatment group. In addition, clinical manifestation 
was no significant difference between oseltamivir-susceptible and 
resistant periods.
Therefore, the establishment of a guideline on the efficient 
treatment of influenza, using oseltamivir that is commonly used for 
treating influenza in Korean pediatric patients and the establishment 
of treatment strategy using a new therapeutic agent are required.   
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